SBIR-STTR Award

Development of a Novel Glaucoma Implant
Award last edited on: 7/13/10

Sponsored Program
SBIR
Awarding Agency
NIH : NEI
Total Award Amount
$891,463
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
Abdul Mateen Ahmed

Company Information

New World Medical Inc

10763 Edison Court
Rancho Cucamonga, CA 91730
   (909) 466-4304
   info@ahmedvalve.com
   www.ahmedvalve.com
Location: Single
Congr. District: 31
County: San Bernardino

Phase I

Contract Number: 1R43EY015587-01
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
2004
Phase I Amount
$100,000
Glaucoma is the leading cause of blindness in the world. Glaucoma is a complex disease with many underlying etiologies. Currently, the only effective treatment is reducing intraocular pressure (lOP) to a clinically safe range. A significant portion of individuals with glaucoma will require surgical intervention to stop progressive optic nerve damage. Current surgical options for refractory glaucoma include trabeculectomy and the use of glaucoma drainage implants. Although antimetabolites have improved success rates for trabeculectomy, their use is associated with unpredictable control of flow, hypotony, wound leaks, capsular fibrosis and infection. Glaucoma tube implants have been gaining popularity, but all current commercially available devices are plagued with a fibrotic response that ultimately limits the outflow facility of these devices and prevents lower lOP. In addition, the fibrous capsule increases the risk of motility disturbances and ptosis and ultimately limits the filtration life of these glaucoma implants. Attempts to modify the fibrotic response to conventional implants have largely been unsuccessful. There have been recent attempts to develop newer generation glaucoma implants using various biocompatible membranes with limited success. We propose a unique implant design consisting of a biocompatible membrane that demonstrates favorable flow and tissue characteristics in an animal model. We propose to integrate an existing implant with the membrane to improve performance. Once constructed, the device will be tested in a rabbit model system. At the time of explant, outflow resistance and histological analysis will be performed to evaluate the function and tissue response of the implant. With improved long-term performance, use of surgical devices would likely increase significantly. Development of a safe and effective glaucoma drainage device will greatly improve our ability to reduce blindness from this common disorder.

Thesaurus Terms:
biomaterial development /preparation, glaucoma, implant angiogenesis, artificial membrane, biological model, biomaterial compatibility, fluid flow, hydrostatic pressure, membrane model histology, laboratory rabbit, medical implant science

Phase II

Contract Number: 2R44EY015587-02
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
2007
(last award dollars: 2008)
Phase II Amount
$791,463

Glaucoma is one of the leading causes of blindness in the world. Glaucoma is a complex disease with many underlying causes. Currently, the only effective treatment is reducing intraocular pressure (IOP) to a clinically safe range. A significant portion of individuals with glaucoma will require surgical intervention to stop progressive optic nerve damage. Current surgical options for refractory glaucomas include trabeculectomy and the use of glaucoma drainage implants. Although antimetabolites have improved success rates for trabeculectomy, their use is associated with unpredictable control of flow, hypotony, wound leaks, capsular fibrosis and infection. Glaucoma tube implants have been gaining popularity, but all current commercially available devices are plagued with a fibrotic response that ultimately limits the outflow facility of these devices and prevents lower IOP. In addition, the fibrous capsule increases the risk of motility disturbances and drooping of the eyelid and ultimately limits the filtration life of these glaucoma implants. Attempts to modify the fibrotic response to conventional implants have largely been unsuccessful. There have been recent attempts to develop newer generation glaucoma implants using various biocompatible membranes with limited success. We successfully demonstrated the feasibility of using a particular biocompatible membrane with a proven glaucoma tube implant to favorably modulate the fibrotic response at the conclusion of our Phase I SBIR grant. For this Phase II application we propose a unique implant design consisting of a biocompatible material that demonstrates advantageous flow and tissue characteristics in animals and humans. We propose to integrate an existing implant with new material to improve performance. The device will be tested in a rabbit model system, and then in humans. The histology, safety, and effectiveness of the implants will be analyzed in the rabbit study. Thereafter, manufacturing of the final prototype for humans will begin along with the development of a mass manufacturing system for the final product. With improved long-term performance of this implant, use of surgical devices would likely increase significantly. Development of this safe and effective glaucoma drainage device will greatly improve the ability to reduce blindness from this common disorder. This project aims to prevent blindness in glaucoma patients through the development of a new glaucoma drainage device